Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Denium Therapeutics, Inc - Common Shares (NQ:MNMD)

13.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 62
Open 13.88
Bid (Size) 13.50 (300)
Ask (Size) 14.20 (400)
Prev. Close 13.88
Today's Range 13.88 - 13.88
52wk Range 4.700 - 15.29
Shares Outstanding 38,595,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat

Performance

YTD
+1.8%
+1.8%
1 Month
+14.9%
+14.9%
3 Month
+13.3%
+13.3%
6 Month
+66.6%
+66.6%
1 Year
+113.7%
+113.7%

More News

Read More
News headline image
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grant
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Reports Q3 2025 Earnings Miss Amid Accelerated Clinical Pipeline Spending ↗
Via Chartmill
Topics Earnings
News headline image
MindMed (MNMD) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MindMed Reports Q3 2025 Financial Results and Business Updates
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Participate in Upcoming Investor Conferences
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grant
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Report Q3 2025 Financial Results on November 6, 2025
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grant
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression ↗
Via Benzinga
News headline image
The Insider Report: Panic Never Pays ↗
Via Benzinga
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
News headline image
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
News headline image
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
News headline image
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today ↗
Via The Motley Fool
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire

Frequently Asked Questions

Is Denium Therapeutics, Inc - Common Shares publicly traded?
Yes, Denium Therapeutics, Inc - Common Shares is publicly traded.
What exchange does Denium Therapeutics, Inc - Common Shares trade on?
Denium Therapeutics, Inc - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Denium Therapeutics, Inc - Common Shares?
The ticker symbol for Denium Therapeutics, Inc - Common Shares is MNMD on the Nasdaq Stock Market
What is the current price of Denium Therapeutics, Inc - Common Shares?
The current price of Denium Therapeutics, Inc - Common Shares is 13.88
When was Denium Therapeutics, Inc - Common Shares last traded?
The last trade of Denium Therapeutics, Inc - Common Shares was at 01/12/26 04:00 PM ET
What is the market capitalization of Denium Therapeutics, Inc - Common Shares?
The market capitalization of Denium Therapeutics, Inc - Common Shares is 535.70M
How many shares of Denium Therapeutics, Inc - Common Shares are outstanding?
Denium Therapeutics, Inc - Common Shares has 536M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.